De-risking drug formulation with AI predictive modelling
Bringing a new drug to market is one of the most time‑consuming and costly assignments within the pharma industry. From…
Partner Content
-
-
Cell and gene therapy patents: What’s accelerating, what’s lagging behind
Cell and gene therapy patent publications totalled 9,786 in the 12 months to May 2026, a decline of approximately 25%…
-
Three years on: How is the industry coping with Annex 1?
Three years after its release, the revised EU GMP Annex 1 stands as an industry watershed, redefining sterile medicine manufacturing.…
-
N. America job signals: What leaders need to know about the healthtech hiring squeeze
Hiring in healthtech across North America has been contracting since mid-2025, and May 2026 data confirmed the trend has not…
-
Early Biomarkers as Predictors of Nephrology Trial Trajectory
Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet…
-
From collection to confidence: why clinical trial data reliability starts early
Every sponsor decision, from dose selection to portfolio prioritisation, depends on whether the evidence generated in a trial is based…
-
Post-marketing oncology studies: Enabling faster recruitment and lower costs
Post-marketing approval studies in clinical research for cancer typically suffer from poor engagement and protracted timelines – driving up costs…
-
The evolution of the ADC market – and what it means for commercial packaging
The ADC market The first antibody drug conjugate (ADC) was approved in 2000 by pairing a cytotoxic chemotherapy agent with…
-
Complementing DepMap: Expanding the toolkit for oncology target discovery and de-risking
With cancer responsible for one in six deaths around the world, precision medicines based on the root cause of the…
-
Designing vial systems to meet the demands of complex biologics
Large molecule medicines are transforming treatment paradigms for many chronic and debilitating diseases, targeting previously “undruggable” pathways and marking a…